Pay in 4 interest-free payments of $43.75 Learn more
Ships within 48 hours · Estimated delivery Sep 10 - Sep 15
HLY78 acts synergistically with Wnt in the embryonic development of zebrafish and increases the expression of the conserved hematopoietic stem cell (HSC) markers
(+)-JQ1 potently decreases expression of both BRD4 target genes
3-[(1s)-1-(2
InChi: InChI=1S/C23H23ClN2O5S/c1-14-21(25-23(29)30-15(2)18-5-3-4-6-19(18)24)22(31-26-14)17-9-7-16(8-10-17)13-32-12-11-20(27)28/h3-10
Formula: C22H19N5O
TAK-875 (Fasiglifam) - GPR40 Agonist. CAS# 1374598-80-7 0083 HLY78 acts synergistically with WntTAK 875 (Fasiglifam), CAS No. 1374598 80 7, is the potent, selective and orally bioavailable partial GPR40 agonist with an EC50 ~14 nM. It has binding affinity to the human GPR40 receptor with Ki of 38 nM and the rat GPR40 receptor with Ki of 140 nM. TAK 875 has no agonist potency to other members of the FFA receptor family with EC50 >10 M. The 2. 3 resolution co complex structure of hGPR40 TAK 875 reveals a unique binding mode of TAK 875 and suggests